CRXT News and Press, Clarus Therapeutics Holdings Inc. From 08/18/22

Second quarter 2022 net revenue increased 46% year-over-year to $4.1 million Second quarter 2022 total prescription growth for JATENZO® increased 23% sequentially and increased 72% year-over-year Immediate reduction in workforce by approximately 40% of total headcou...

3 Tips for Trading Penny Stocks in 2022 Is trading penny stocks worth it right now? The answer may depend on your goals and investment strategy. If you’re looking to make a quick profit, then there are plenty of ways to make money with penny stocks . However, it’s cruc...

JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., July 28, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT)...

3 Hot Penny Stocks to Watch During Trading This Week With another dismal start to a week for penny stocks and blue chips, there is a lot for investors to know right now. Although trading penny stocks has not been easy lately, there have been some opportunities for investors to profi...

3 Hot Penny Stocks to Add to Your Watchlist in July With so many penny stocks to choose from, it can be tough to know where to start. And in 2022, there is a myriad of factors that are causing major movement in the stock market. As traders, the best course of action for making money w...

JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., June 09, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nas...

Clarus Therapeutics (NASDAQ:CRXT) said on Wednesday that the U.S. Patent and Trademark Office had issued a new patent for claims that cover its oral testosterone replacement product, Jatenzo. (CRXT) shares rose 5.3% before the bell. The patent will expire in January 2027. ...

JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions Clarus plans to list this patent in FDA’s Orange Book, which would bring the total number of Orange Book-...

Clarus Therapeutics Holdings, Inc. (CRXT) Q1 2022 Earnings Conference Call May 16, 2022, 05:15 PM ET Company Participants Bob Dudley - Founder, President and CEO Ric Peterson - CFO Frank Jaeger - Chief Commercial Officer Conference Call Participants Presentation Operator Thank you for joining...

Clarus Therapeutics press release (NASDAQ:CRXT): Q1 GAAP EPS of -$0.61 misses by $0.15. Revenue of $4.01M (+72.1% Y/Y) misses by $0.94M. For further details see: Clarus Therapeutics GAAP EPS of -$0.61 misses by $0.15, revenue of $4.01M misses by $0.94M